McMaster University

McMaster University

Peter Margetts

, MD, PhD

Associate Member
Pathology and Molecular Medicine

Division: Molecular Medicine

Associate Professor, Medicine
Division of Nephrology
Director, MD/PhD Program

St. Joseph’s Hospital, T3309
905-522-1155, ext. 32299

Currently accepting Graduate Students

Peter Margetts

Faculty Biography

Education and Professional Standing

  • PhD, McMaster University, 2003
  • MD, McMaster University, 1994


Research Focus

I am investigating the pathology of tissue fibrosis pertaining to kidneys and the peritoneum. I am interested in cytokines, growth factors, and cells involved in the progression or maintenance of fibrosis; the role of angiogenesis in fibrosis; and gene therapy and pharmacologic techniques to interfere with fibrosis.

I am specifically studying the process of epithelial mesenchymal transition in peritoneal fibrosis; a central process in the early stage of fibrosis. I am also interested in factors involved in the maintenance of fibrosis, including metalloproteinases and their inhibitors. I have been studying the role of transforming growth factor beta in angiogenesis and specifically the regulation of angiopoietins in fibrotic tissue. These studies have wide applicability to scar formation, and ischemic disease. We have used adenovirus mediated gene therapy to inhibit fibrosis and angiogenesis and are exploring other gene therapy techniques. I have also studied the use of novel pharmacologic agents for modulating the fibrogenic response; specifically the immunomodulatory agents rapamycin and mycophenolate.

We use adenovirus mediated gene transfer, animal models of renal disease and peritoneal fibrosis, transgenic animals, cell culture techniques, quantitative real time PCR, western blot, ELISA, zymography, histology, fluorescent and light immunohistochemistry, EM, and laser capture microdissection.

Clinical Focus

I am a staff nephrologist with clinical interest in end-stage kidney disease and dialysis.

Academic Interests

I am presently director of McMaster’s MD/PhD program.

Selected Publications

  • Oh K-W, Youn MO, Song A, Hwang Y-H, Margetts PJ, Lee H, Ahn C, Gu C. Dialysate interleukin-6 as the determinant factor of the baseline peritoneal solute transport in incident peritoneal dialysis patients. (Accepted by Nephrol Dial Transport November 2009).
  • Patel P, West-Mays J, Kolb M, Rodrigues JC, Hoff CM, Margetts PJ. Platelet derived growth factor B and epithelial mesenchymal transition of peritoneal mesothelial cells.  Matrix Biol 2010; 29: 97-106.
  • Patel P, Sekiguchi Y, Oh K-W, Kolb M, Margetts PJ. Smad3 dependent and independent pathways are involved in peritoneal membrane injury.  Kidney Int 2010; 77: 319-328.
  • Salama S, Cina DP, Margetts PJ. Cutaneous Presentation of Post-Renal Transplant Lymphoproliferative Disorder: A Case Series. J Cutan Pathol 2009. Nov 19 (epub).
  • Decologne N, Wettstein G, Kolb M, Margetts P, Garrido C, Camus P, Bonniaud. Bleomycin induces pleural and subpleural fibrosis in the presence of carbon black particles.  Eur Respir J 2010; 35: 176-185. 
  • Gangi A, Brimble KS, Margetts PJ. Association between Markers of Inflammation and Fibrosis and Hypervolemia in Peritoneal Dialysis Patients.  Blood Purif 2009, 28: 354-358.
  • Farkas L, Ask K, Moller A, Farkas D, Margetts P, Gauldie J, Inman M, Kolb M. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats.  J Clin Invest 2009; 119: 1298-1311. 
  • MacGillvary L, Hernandez J, Maedler C, Chu D, Margetts P. Developing Clinical Scientists: The MD/PhD Program at McMaster University. McMaster University Medical Journal 2009; 6:5-10.
  • Liu L, Shi CX, Ghayur A, Zhang C, Su JY, Hoff CM, Margetts PJ.  Prolonged peritoneal gene expression using a helper-dependent adenovirus.  Petri Dial Int 2009; 29:508-518. 
  • Moeller A, Gilpin S, Ask K, Cox G, Cook DJ, Gauldie J, Margetts PJ. Farkas L, Dobranowski J, Boylan C, O’Byrne PM, Striedter RM, Kolb MRJ. Circulating fibrocytes are an indicator or poor prodnosis in indiopathic pulmponary fibrosis. AJRCCM 2009; 179: 588-594. 
  • Cina D, Patel P,  Bethune C, Thoma J, Rodrigues JC, Hoff CM, Margetts PJ. Peritoneal morphological and functional changes associated with platelet derived growth factor.  Nephrol Dial Transplant 2009; 24: 448-457. 
  • Zhang J, Oh K-H, Xu H, Margettes PJ. Vascular endothelial growth factor expression in peritoneal mesothelial cells undergoing transdifferentiation.  Perit Dial Int 2008; 28: 497-504. 
  • Gangji AS, Helal BA, Churchill DN, Brimble KS, Margetts PJ.  Association between N terminal propeptide B-type natriuretic peptide and markers of hypervolemia.  Perit Dial Int 2008; 28: 308-311.
  • Decologne N, Kolb M, Margetts PJ, Menetrier F, Artur Y, Garrido C, Gauldie J, Camu P, Bonniaud P.  Transforming growth factor beta 1 induced progressive pleural scarring and subpleural fibrosis. J Immunol 2007; 179: 6043-6051. 
  • Brimble KS, Walker M, Margetts PJ, Kundhal KK, Rabbat CG.  Meta-Analsis: Peritoneal membrane transport, mortality and technique failure in peritoneal dialysis. J Am Soc Nephrol 2006; 17: 2591-2598. 
Valid XHTML 1.0 Transitional Level Double-A conformance, W3C WAI Web Content Accessibility Guidelines 2.0